title: [FOLFOX].
abstract: In metastatic colorectal cancer, a combination of Leucovorin (LV) and fluorouraci (l FU) with oxaliplatin (FOLFOX) is a standard first-line regimen. The two limiting toxicities of FOLFOX are neutropenia and the specific reversible sensory neuropathy of oxaliplatin. The cumulative neurotoxicity often requires therapy to be stopped. Immediate hypersensitive reactions (anaphylaxis) have been noted as often as to 0.6 percent. We should pay sufficient attention to side effects of FOLFOX.
authors.affiliation: National Hospital Organization, Osaka National Hospital.
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Mishima
authors.forename: Masakazu
authors.initials: M
authors.lastname: Ikenaga
authors.forename: Toshimasa
authors.initials: T
authors.lastname: Tsujinaka
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Yasui
authors.forename: Masaki
authors.initials: M
authors.lastname: Kashiwazaki
authors.forename: Michihiko
authors.initials: M
authors.lastname: Miyazaki
authors.forename: Motohiro
authors.initials: M
authors.lastname: Hirao
authors.forename: Kazumasa
authors.initials: K
authors.lastname: Fujitani
authors.forename: Shouji
authors.initials: S
authors.lastname: Nakamori
mesh_terms: D000707:Anaphylaxis / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D019983:Guideline Adherence; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects; D009369:Neoplasms / Q000188:drug therapy*; D009503:Neutropenia / Q000139:chemically induced; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D017410:Practice Guidelines as Topic
chemical_list: D009944:Organoplatinum Compounds; D002955:Leucovorin; D005472:Fluorouracil